# A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

> **NCT01511432** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 64 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** telaprevir formulation A
- **DRUG:** telaprevir Formulation B
- **DRUG:** telaprevir Formulation C
- **DRUG:** telaprevir Formulation D

## Key facts

- **NCT ID:** NCT01511432
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-06
- **Final completion:** 2012-07
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2012-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01511432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01511432, "A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01511432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*